Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
Adeno-associated virus (AAV) has become an increasingly popular viral vector for gene therapy. Currently, there are two approved AAV-based gene therapies, and the number of clinical trials is steadily increasing. As with most viral vector therapies, their production is labour intensive and expensive due to the use of adherent cell culture production processes. For process intensification, the industry has begun to utilize bioreactors. Here, we highlight our development of a suspension based AAV upstream production process to provide a more efficient and cost-effective bioprocessing solution for large scale production